J&J, Boston U partner to map early detection biomarkers for lung cancer

The Johnson & Johnson Innovation LLC unit of Johnson & Johnson (NYSE:JNJ) and Boston University unveiled a five-year collaboration to identify biomarkers for early stage lung cancer. The research includes a precancer genome atlas (PCGA) study, and the partners aim to find new therapeutic targets and develop interceptive products. The partners said terms are not disclosed.

Boston University Professor of Medicine, Pathology and Bioinformatics Avi Spira will direct a newly established J&J Innovation Lung Cancer Center located at the university. J&J hired Spira as global head of its lung cancer initiative...